" class="no-js "lang="en-US"> National AIDS Trust - Medtech Alert
Tuesday, April 16, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
National AIDS Trust | Pharmtech Focus

National AIDS Trust

About National AIDS Trust

National AIDS Trust

We’re the UK’s HIV rights charity. We work to stop HIV from standing in the way of health, dignity and equality, and to end new HIV transmissions. Our expertise, research and advocacy secure lasting change to the lives of people living with and at risk of HIV.

Related Story

News

 Blood Donation to be Made More Inclusive | Pharmtech Focus

Blood Donation to be Made More Inclusive

October 11 2021

People who want to donate blood, particularly Black African donors, will be able to do […]